Equities Research Analysts’ Upgrades for November, 8th (BCI, EFX, GDI, PTMN, QCOM, STN, VECO, VGR, VNTR, VRNA)

Equities Research Analysts’ upgrades for Friday, November 8th:

New Look Vision Group (TSE:BCI) was upgraded by analysts at National Bank Financial from a sector perform rating to an outperform rating. National Bank Financial currently has C$36.00 price target on the stock.

Enerflex (TSE:EFX) was upgraded by analysts at National Bank Financial from a sector perform rating to an outperform rating. They currently have C$18.00 target price on the stock.

GDI Integrated Facility Services (TSE:GDI) was upgraded by analysts at CIBC from a neutral rating to an outperform rating. They currently have C$35.00 price target on the stock, up from their previous price target of C$31.00.

Portman Ridge Finance (NASDAQ:PTMN) was upgraded by analysts at LADENBURG THALM/SH SH from a neutral rating to a buy rating.

QUALCOMM (NASDAQ:QCOM) was upgraded by analysts at DZ Bank AG from a sell rating to a hold rating. They currently have $92.00 price target on the stock.

Stantec (TSE:STN) (NYSE:STN) was upgraded by analysts at CIBC from a neutral rating to an outperform rating. The firm currently has C$40.00 target price on the stock, up from their previous target price of C$35.00.

Stantec (TSE:STN) (NYSE:STN) was upgraded by analysts at TD Securities from a hold rating to a buy rating. They currently have C$39.00 target price on the stock, up from their previous target price of C$33.00.

Stantec (TSE:STN) (NYSE:STN) was upgraded by analysts at National Bank Financial from a sector perform rating to an outperform rating. They currently have C$36.00 target price on the stock, up from their previous target price of C$30.50.

Veeco Instruments (NASDAQ:VECO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $18.00 target price on the stock. According to Zacks, “Veeco Instruments Inc. is engaged in the design, development, manufacture and support of thin film process equipment, primarily sold to make electronic devices. Veeco’s process equipment solutions enable the manufacture of LEDs, power electronics, hard drives, MEMS and wireless chips. They are the market leader in MOCVD, MBE, Ion Beam and other advanced thin film process technologies. The Company’s portfolio of technology solutions focus on market areas, including Lighting, Display & Power Electronics; Advanced Packaging, micro-electromechanical systems (MEMS) & radio frequency (RF); Scientific & Industrial, and Data Storage. The Company’s System products include Metal Organic Chemical Vapor Deposition Systems, Precision Surface Processing Systems, Ion Beam Etch and Deposition Systems, Molecular Beam Epitaxy Systems, and Other Deposition and Industrial Products. The Company’s original name Veeco stood for Vacuum Electronic Equipment Company. “

Vector Group (NYSE:VGR) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. The firm currently has $13.00 target price on the stock. According to Zacks, “BROOKE GROUP LTD. is principally engaged in the manufacture and sale of cigarettes and the sale of information processing systems. It also has investments in a number of additional companies engaged in a diverse group of businesses. “

Venator Materials (NYSE:VNTR) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Venator Materials PLC is a manufacturer and marketer of chemical products. The company’s product comprises a broad range of pigments and additives that bring color and vibrancy to building, protect and extend product life and reduce energy consumption. Its operating segment consists of Titanium Dioxide, which consists of our TiO2 business, and Performance Additives, which consists of our functional additives, color pigments, timber treatment and water treatment businesses. Venator Materials PLC is headquartered in The Woodlands, Texas. “

VERONA PHARMA P/S (NASDAQ:VRNA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $5.00 target price on the stock. According to Zacks, “Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom. “

Verint Systems (NASDAQ:VRNT) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Verint Systems Inc. is a leading provider of analytic solutions for communications interception, digital video security and surveillance, and enterprise business intelligence. “

Vista Outdoor (NYSE:VSTO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $7.75 target price on the stock. According to Zacks, “Vista Outdoor Inc. develops, manufacture and distribute optics, accessories and eyewear. The Company operates in two segments: Shooting Sports and Outdoor Products. Its product consist of binoculars, laser rangefinders, riflescopes, trail cameras, archery accessories, blinds, decoys, game calls, gun care products, mounts, powder, reloading equipment, targets, target systems, safety and protective eyewear, fashion and sports eyewear. The company’s product portfolio include Bushnell(R), Primos(R), Bollè(R), Serengeti(R), Cèbè, RCBS(R), Hoppe’s(R), Uncle Mike’s(R), Gold Tip(R), Weaver(R) and Tasco(R). Vista Outdoor Inc. is headquartered in Utah. “

vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $1.50 price target on the stock. According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “

Receive News & Ratings for New Look Vision Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for New Look Vision Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply